DCF Tool

PDEX

Pro-Dex Inc. (co) – Surgical and Medical Instrument Manufacturing
for over 40 years pro-dex has successfully collaborated with several of the world’s largest providers of medical and dental devices. wherever you are in your process, we can help you. whether your product is partially or fully-designed, we have the capabilities to deliver the services you’re in need of. our staff is experienced in providing engineering, precision machining and fabrication, electro-mechanical assembly, components, sub-assemblies, finished products, and flexible volumes - all with exceptional service. as we’ve experienced growth at pro-dex, we’ve recognized the need to expand our engineering services division. we can offer you powerful solutions including consulting, varying engineering services, and staffing. we’re here to connect you with engineering support for the mechanical, electrical, and manufacturing needs of your company. while we may have built our business around the design and manufacturing for medical oem’s, we have since found increased success working wit
Analysis Results
Intrinsic Value $45.93
Latest Price $17.15
Relative Value 63% undervalued
Thoughts on this result? Let us know.
Ad
Cash Flow (Millions)
Analysis Parameters
%
%
%
New Ticker
Ad
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of 6.3%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 4.1%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of 6.3%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (million) Present value (million)
2024 4.59 4.41
2025 4.88 4.5
2026 5.19 4.6
2027 5.51 4.7
2028 5.86 4.8
Terminal Value

Assuming the company was sold after the projection period at an exit multiple of 30, the terminal value of the company would be 176 million. This corresponds to a present value of 138 million.

Intrinsic Value Per Share

The total present value of the projected cash flows is 23.0 million. Adding in the terminal value gives a total present value of 161 million.

There are presently 3.51 million outstanding shares, so the intrinsic value per share is 45.93.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 30,979,000
Current Cash 4,070,000
Current Liabilities 9,676,000
Current Debt 3,827,000
Non-Cash Working Capital (NCWC) 21,060,000
Change in NCWC -433,000
EBIT 5,762,000
Tax Provision 2,354,000
Depreciation and Amortization 857,000
Capital Expenditure -974,000
Unlevered Free Cash Flow 3,773,333
Current Assets 31,166,000
Current Cash 1,604,000
Current Liabilities 11,354,000
Current Debt 3,285,000
Non-Cash Working Capital (NCWC) 21,493,000
Change in NCWC 6,132,000
EBIT 5,158,000
Tax Provision 851,000
Depreciation and Amortization 726,000
Capital Expenditure -1,671,000
Unlevered Free Cash Flow 9,412,263
Current Assets 25,013,000
Current Cash 5,016,000
Current Liabilities 5,872,000
Current Debt 1,236,000
Non-Cash Working Capital (NCWC) 15,361,000
Change in NCWC 6,244,000
EBIT 4,525,000
Tax Provision 1,176,000
Depreciation and Amortization 686,000
Capital Expenditure -8,268,000
Unlevered Free Cash Flow 2,241,141
Current Assets 22,674,000
Current Cash 8,981,000
Current Liabilities 5,227,000
Current Debt 651,000
Non-Cash Working Capital (NCWC) 9,117,000
Change in NCWC 1,373,000
EBIT 7,061,000
Tax Provision 1,790,000
Depreciation and Amortization 573,000
Capital Expenditure -519,000
Unlevered Free Cash Flow 6,888,507
Current Assets 21,783,000
Current Cash 10,391,000
Current Liabilities 4,270,000
Current Debt 622,000
Non-Cash Working Capital (NCWC) 7,744,000
Change in NCWC 1,422,000
EBIT 4,991,000
Tax Provision 1,299,000
Depreciation and Amortization 438,000
Capital Expenditure -1,387,000
Unlevered Free Cash Flow 4,273,746
Current Assets 16,233,000
Current Cash 7,408,000
Current Liabilities 2,538,000
Current Debt 35,000
Non-Cash Working Capital (NCWC) 6,322,000
Change in NCWC 1,846,000
EBIT 3,405,000
Tax Provision 989,000
Depreciation and Amortization 557,000
Capital Expenditure -923,000
Unlevered Free Cash Flow 3,594,752
Current Assets 11,921,000
Current Cash 4,923,000
Current Liabilities 2,580,000
Current Debt 58,000
Non-Cash Working Capital (NCWC) 4,476,000
Change in NCWC -397,000
EBIT 2,847,000
Tax Provision -2,089,000
Depreciation and Amortization 555,000
Capital Expenditure -638,000
Unlevered Free Cash Flow 2,367,000
Current Assets 9,218,000
Current Cash 2,294,000
Current Liabilities 2,077,000
Current Debt 26,000
Non-Cash Working Capital (NCWC) 4,873,000
Change in NCWC 825,000
EBIT 771,000
Tax Provision 25,000
Depreciation and Amortization 614,000
Capital Expenditure -335,000
Unlevered Free Cash Flow 1,852,243
Current Assets 8,408,000
Current Cash 697,000
Current Liabilities 3,694,000
Current Debt 31,000
Non-Cash Working Capital (NCWC) 4,048,000
Change in NCWC 462,000
EBIT -902,000
Tax Provision -44,000
Depreciation and Amortization 578,000
Capital Expenditure -244,000
Unlevered Free Cash Flow -106,000
Current Assets 8,893,000
Current Cash 3,188,000
Current Liabilities 2,127,000
Current Debt 8,000
Non-Cash Working Capital (NCWC) 3,586,000
Change in NCWC 228,000
EBIT -814,000
Tax Provision -104,000
Depreciation and Amortization 527,000
Capital Expenditure -155,000
Unlevered Free Cash Flow -214,000
Current Assets 7,347,000
Current Cash 1,680,000
Current Liabilities 2,314,000
Current Debt 5,000
Non-Cash Working Capital (NCWC) 3,358,000
Change in NCWC 78,000
EBIT -1,895,000
Tax Provision -39,000
Depreciation and Amortization 582,000
Capital Expenditure -86,000
Unlevered Free Cash Flow -1,321,000
Current Assets 9,497,000
Current Cash 4,112,000
Current Liabilities 2,879,000
Current Debt 774,000
Non-Cash Working Capital (NCWC) 3,280,000
Change in NCWC -207,000
EBIT -1,365,000
Tax Provision -441,000
Depreciation and Amortization 647,000
Capital Expenditure -341,000
Unlevered Free Cash Flow -1,266,000

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.